- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal, CME: Continuing Medical Education Questions: May 2023. (Pubmed Central) - May 7, 2023 No abstract available Article Title: Linaclotide Reduced Response Time for Irritable Bowel Syndrome with Constipation Symptoms: Analysis of Four Randomized Controlled Trials.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
LINACLOTIDE IS PROTECTIVE AGAINST RENAL ISCHEMIA-REPERFUSION INJURY (Focussed Oral Room 5) - May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_884; We would like to apply this finding to human renal transplantation in the future to prevent renal function deterioration due to I/R. 0.55 * Cr(mg/dl) 0.5 0.45 0.4 0.35 0.3 0.25 sham 0 40 200 400 Ischemic reperfusion(+) Linaclotide ( ?/kg/day)
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date: Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation (clinicaltrials.gov) - May 3, 2023 P4, N=23, Active, not recruiting, 0.55 * Cr(mg/dl) 0.5 0.45 0.4 0.35 0.3 0.25 sham 0 40 200 400 Ischemic reperfusion(+) Linaclotide ( ?/kg/day) Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- |||||||||| Journal: An Update on The Use of Pharmacotherapy for Opioid-Induced Bowel Dysfunction. (Pubmed Central) - Feb 27, 2023
The fundamental reason is the lack of head-to-head clinical trials providing inter- and intragroup comparisons between PAMORAs, laxatives, and secretagogue agents. These investigations must be accompanied by further valid biopharmaceutical and economic evaluations, paving the way for rational clinical judgment in each context.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion: Liberty: Evaluate the Safety of Linaclotide in IBS-C Patients in China (clinicaltrials.gov) - Feb 14, 2023 P=N/A, N=3017, Completed, These investigations must be accompanied by further valid biopharmaceutical and economic evaluations, paving the way for rational clinical judgment in each context. Active, not recruiting --> Completed
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide. (Pubmed Central) - Feb 12, 2023 Linaclotide is a 14-amino acid residue peptide approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C), which activates guanylate cyclase C to accelerate intestinal transit. Here we show a new method for the synthesis of linaclotide through the completely selective formation of three disulfide bonds in satisfactory overall yields via mild oxidation reactions of the solid phase and liquid phase, using 4-methoxytrityl (Mmt), diphenylmethyl (Dpm) and 2-nitrobenzyl (O-NBn) protecting groups of cysteine as substrate, respectively.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Enrollment open, Adverse events: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (clinicaltrials.gov) - Jan 5, 2023 P3, N=100, Recruiting, The method is also compatible with NCL buffer, and we highlight the robustness of the approach through the one-pot disulfide reduction/multidesulfurization of linaclotide, aprotinin, and wheat protein. Not yet recruiting --> Recruiting
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Intestinal neuropod GUCY2C regulates visceral pain. (Pubmed Central) - Dec 23, 2022 Importantly, eliminating GUCY2C selectively in neuropod cells also increased nociceptive signaling and VP that was refractory to linaclotide. In the context of loss of GUCY2C hormones in patients with VP, these observations suggest a specific role for neuropod GUCY2C signaling in the pathophysiology and treatment of these pain syndromes.
- |||||||||| Review, Journal: Management of Opioid-induced Constipation in Older Adults. (Pubmed Central) - Dec 13, 2022
Because of the complex nature of absorption, distribution, metabolism, and excretion in the aging population, all agents used to treat OIC must be evaluated individually and reevaluated as patients continue to age. This review will serve as a guide to managing OIC in older adults.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial completion date, Trial primary completion date: Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer (clinicaltrials.gov) - Dec 1, 2022 P2, N=230, Recruiting, Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- |||||||||| Journal: Pharmacotherapeutic advances for chronic idiopathic constipation in adults. (Pubmed Central) - Nov 22, 2022
In addition, relamorelin, a ghrelin agonist, seems promising for accelerating colonic transit...On the other hand, the experience with these new agents is still limited, especially for long-term treatment. Another important point is that these new treatments for chronic idiopathic constipation are not available worldwide and their use could be somewhat limited by their still relatively high cost.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Trial initiation date: SYSCO-VR: System Constellations in Virtual Reality (VR) (clinicaltrials.gov) - Nov 1, 2022 P=N/A, N=128, Not yet recruiting, Similarly, most additional efficacy endpoints showed no improvement with MD-7246 relative to placebo. Initiation date: Oct 2022 --> Mar 2023
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Enrollment open, Trial initiation date: GCC Agonist Signal in the Small Intestine (clinicaltrials.gov) - Oct 28, 2022 P1, N=43, Recruiting, Initiation date: Oct 2022 --> Mar 2023 Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Oct 2022
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Journal: Linaclotide Reduced Response Time for Irritable Bowel Syndrome with Constipation Symptoms: Analysis of Four Randomized Controlled Trials. (Pubmed Central) - Oct 14, 2022 Although treatment responses with linaclotide occurred in >50% of patients with IBS-C within 4 weeks of treatment initiation, benefits for individual abdominal symptoms and/or CSBM frequency can still occur between 4 and 12 weeks. A lack of improvement in one symptom does not negate the possibility of response for others, highlighting the importance of discussing all symptoms with patients and not assuming treatment futility at 4 weeks.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
Neuropod mediated changes to DRG electrical properties potentially play a role in the pathophysiology of visceral abdominal pain (SDCC Halls B-H) - Oct 10, 2022 - Abstract #Neuroscience2022NEUROSCIENCE_8527; Supporting this role, the synthetic GUCY2C agonist linaclotide has significant analgesic effects in CVP...These results strongly suggest a new pathway of visceral pain signaling involving GUCY2C-high neuropod EECs that communicate with DRG neurons to regulate their intrinsic excitability and thereby nociceptive signaling. Therefore, GUCY2C-high neuropod EECs emerge as therapeutic targets to develop new interventions to treat CVP.
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Trial initiation date: GCC Agonist Signal in the Small Intestine (clinicaltrials.gov) - Sep 29, 2022 P1, N=43, Not yet recruiting, Ultimately, a multidisciplinary team approach is required to properly assess the risks and benefits to achieve good clinical outcomes. Initiation date: Oct 2022 --> Mar 2023
- |||||||||| Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health
Review, Journal: Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. (Pubmed Central) - Sep 20, 2022 Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In this context, GUCY2C satisfies many characteristics of a compelling target and biomarker for gastrointestinal malignancies.
|